CD163 and metabolic dysfunction-associated steatohepatitis: Furthermore, the macrophage-targeting principle with GCs or other anti-inflammatory drugs might also be relevant for other inflammatory diseases, including other liver diseases such as acute alcoholic hepatitis, which shares pathology with NASH and has a several-fold accumulation of CD163-positive macrophages in the liver.59, 60 This disease has high mortality and there is an imminent need for new targeted approaches.26